Trends in Multiple Sclerosis Therapy Examined in New Insightful FirstWord ... San Francisco Chronicle (press release) ... beta-1b; Novartis) Forecast; BG-12 (dimethyl fumarate; Biogen) Forecast; Aubagio (teriflunomide; Sanofi) Forecast; Laquinimod (Teva/Active Biotech) Forecast; Lemtrada (alemtuzumab; Genzyme/Sanofi) Forecast; Daclizumab HYP (Biogen/Abbott) Forecast ... |
